Allergan

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Allergan [NCT01089751]

Description:  This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with the incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

Drug: Sanctura 60 mg; Drug: Placebo

Primary Investigator: Karram

Drug/Device Information
Female overactive bladder
Sanctura 60 mg. vs. Placebo
Muscarinic antagonist
Allergan
Major Inclusion and Exclusion
Women age 18-75 with urge incontinence > 3 months
On Detrol LA 4mg every day for at least 1 month
Overactive bladder syndrome
Must be on ≥ 5 medications or supplements not being used to treat overactive bladder